Perrigo Company Net Income Over Time
| PRGO Stock | USD 13.74 0.21 1.51% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out Perrigo Company Performance and Perrigo Company Correlation. Will Pharmaceuticals sector continue expanding? Could Perrigo diversify its offerings? Factors like these will boost the valuation of Perrigo Company. Anticipated expansion of Perrigo directly elevates investor willingness to pay premium valuations. Accurate valuation requires analyzing both current fundamentals and future growth trajectories. Every Perrigo Company data point contributes insight, yet successful analysis hinges on identifying the most consequential variables.
Quarterly Earnings Growth (0.64) | Dividend Share 1.164 | Earnings Share (0.21) | Revenue Per Share | Quarterly Revenue Growth (0.04) |
Investors evaluate Perrigo Company using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Perrigo Company's intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Seasoned market participants apply comprehensive analytical frameworks to derive fundamental worth and identify mispriced opportunities. External factors like market trends, sector rotation, and investor psychology can cause Perrigo Company's market price to deviate significantly from intrinsic value.
It's important to distinguish between Perrigo Company's intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Perrigo Company should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Perrigo Company's market price signifies the transaction level at which participants voluntarily complete trades.
Cross Equities Net Income Analysis
Compare Perrigo Company and related stocks such as HUTCHMED DRC, Bausch Health Companies, and Supernus Pharmaceuticals Net Income Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| HCM | (6.8 M) | 710.2 K | 3.6 M | 5.9 M | 5.4 M | 8 M | 11.7 M | (26.7 M) | (74.8 M) | (103.7 M) | (125.7 M) | (194.6 M) | (360.8 M) | 100.8 M | 37.7 M | 34 M | 35.7 M |
| BHC | 3.9 M | 159.6 M | (116 M) | (866.1 M) | 881 M | (268.7 M) | (2.4 B) | 2.4 B | (4.1 B) | (1.8 B) | (559 M) | (948 M) | (225 M) | (592 M) | (46 M) | (41.4 M) | (43.5 M) |
| SUPN | (17.3 M) | 56 M | (46.3 M) | (92.3 M) | 19.9 M | 14 M | 91.2 M | 57.3 M | 111 M | 113.1 M | 127 M | 53.4 M | 60.7 M | 1.3 M | 73.9 M | 84.9 M | 89.2 M |
| HTFL | (95.7 M) | (95.7 M) | (95.7 M) | (95.7 M) | (95.7 M) | (95.7 M) | (95.7 M) | (95.7 M) | (95.7 M) | (95.7 M) | (95.7 M) | (95.7 M) | (95.7 M) | (95.7 M) | (96.4 M) | (86.8 M) | (91.1 M) |
| ATEC | 91.9 K | (22.2 M) | (15.5 M) | (82.2 M) | (12.9 M) | (178.7 M) | (30.3 M) | (2.3 M) | (29 M) | (57 M) | (79 M) | (143 M) | (151.3 M) | (186.6 M) | (162.1 M) | (145.9 M) | (138.6 M) |
| LIVN | (5.1 M) | 36.1 M | 46.4 M | 54.9 M | 54.9 M | 57.8 M | (62.8 M) | (25.1 M) | (189.4 M) | (157.6 M) | (348.8 M) | (135.8 M) | (86.2 M) | 17.5 M | 63.2 M | 56.9 M | 59.8 M |
| TARS | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (1.3 M) | (4.7 M) | (26.8 M) | (13.8 M) | (62.1 M) | (135.9 M) | (115.6 M) | (104 M) | (98.8 M) |
| SGRY | 1.9 M | 1.9 M | 1.9 M | (9.1 M) | (65.9 M) | 1.4 M | 9.5 M | (53 M) | (205.7 M) | (74.8 M) | (116.1 M) | (70.9 M) | (54.6 M) | (11.9 M) | (168.1 M) | (151.3 M) | (143.7 M) |
| SRRK | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (16.2 M) | (25 M) | (49.3 M) | (49.7 M) | (85 M) | (131.8 M) | (131.6 M) | (165.8 M) | (246.3 M) | (221.7 M) | (210.6 M) |
| FOLD | (6.8 M) | (44.4 M) | (48.8 M) | (59.6 M) | (68.9 M) | (132.1 M) | (200 M) | (284 M) | (349 M) | (356.4 M) | (276.9 M) | (250.5 M) | (236.6 M) | (151.6 M) | (56.1 M) | (50.5 M) | (53 M) |
Perrigo Company and related stocks such as HUTCHMED DRC, Bausch Health Companies, and Supernus Pharmaceuticals Net Income description
Net income is one of the most important fundamental items in finance. It plays a large role in Perrigo Company financial statement analysis. It represents the amount of money remaining after all of Perrigo Company PLC operating expenses, interest, taxes and preferred stock dividends have been deducted from a company total revenue.My Equities
My Current Equities and Potential Positions
| Perrigo Company PLC | PRGO |
Specialization | Health Care, Pharmaceuticals, Biotechnology & Life Sciences |
| Business Address | The Sharp Building, |
| Exchange | New York Stock Exchange |
USD 13.74
Check out Perrigo Company Performance and Perrigo Company Correlation. You can also try the Equity Analysis module to research over 250,000 global equities including funds, stocks and ETFs to find investment opportunities.
Perrigo Company technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.